Omeprazol Actavis (Omeprazole)

Omeprazol Actavis is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, blocking the final step of acid secretion. This inhibition markedly reduces gastric acidity, allowing mucosal healing and symptom relief in acid‑related disorders.

Omeprazol Actavis may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or vomiting: transient gastrointestinal upset.
• Abdominal pain or flatulence: mild discomfort.
• Constipation: occasional bowel habit change.
• Dry mouth: reduced salivary flow.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis in vulnerable patients.
• Acute interstitial nephritis: renal inflammation requiring medical evaluation.
• Hypomagnesemia: low serum magnesium with prolonged use.
• Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term therapy.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Hepatic dysfunction: elevated liver enzymes or jaundice.

Before starting Omeprazol Actavis, consider the following safety measures:

• Assess renal function: adjust use in severe renal impairment.
• Review hepatic status: use with caution in liver disease.
• Evaluate long‑term need: limit duration when possible to reduce fracture risk.
• Monitor electrolytes: check magnesium levels during extended therapy.
• Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs. Careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atorvastatin: increased plasma concentration, higher risk of myopathy.
• Warfarin: potential enhancement of anticoagulant effect, monitor INR.

Moderate Interactions (Monitor Closely)

• Digoxin: elevated serum levels, watch for toxicity.
• Methotrexate: reduced renal clearance, risk of toxicity.
• HIV protease inhibitors (e.g., ritonavir): altered absorption, adjust dosing as needed.